Cover Image
市場調查報告書

神經纖維瘤:開發中產品分析

Neurofibromatoses - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363114
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
神經纖維瘤:開發中產品分析 Neurofibromatoses - Pipeline Review, H2 2016
出版日期: 2016年12月21日 內容資訊: 英文 71 Pages
簡介

本報告提供神經纖維瘤治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

神經纖維瘤概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

神經纖維瘤:企業開發中的治療藥

神經纖維瘤:大學/機關研究中的治療藥

神經纖維瘤:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

神經纖維瘤:企業開發中的產品

神經纖維瘤:大學/機關研究中的產品

神經纖維瘤治療藥的開發企業

  • Alexion Pharmaceuticals, Inc.
  • Arno Therapeutics, Inc.
  • AstraZeneca Plc
  • CalAsia Pharmaceuticals, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Lixte Biotechnology Holdings, Inc.
  • Novartis AG
  • Pfizer Inc.

神經纖維瘤:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

神經纖維瘤:暫停中的計劃

神經纖維瘤:中止開發的產品

神經纖維瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8833IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses - Pipeline Review, H2 2016, provides an overview of the Neurofibromatoses (Genetic Disorders) pipeline landscape.

Neurofibromatosis (commonly abbreviated NF; neurofibromatosis type 1 is also known as von Recklinghausen disease) is a genetically-inherited disorder in which the nerve tissue grows tumors (neurofibromas) that may be benign or may cause serious damage by compressing nerves and other tissues. The disorder affects all neural crest cells (Schwann cells, melanocytes and endoneurial fibroblasts). Cellular elements from these cell types proliferate excessively throughout the body, forming tumors; melanocytes also function abnormally in this disease, resulting in disordered skin pigmentation and cafe au lait spots. The tumors may cause bumps under the skin, colored spots, skeletal problems, pressure on spinal nerve roots, and other neurological problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neurofibromatoses (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase 0, Preclinical and Discovery stages are 3, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Neurofibromatoses (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neurofibromatoses Overview
  • Therapeutics Development
    • Pipeline Products for Neurofibromatoses - Overview
    • Pipeline Products for Neurofibromatoses - Comparative Analysis
  • Neurofibromatoses - Therapeutics under Development by Companies
  • Neurofibromatoses - Therapeutics under Investigation by Universities/Institutes
  • Neurofibromatoses - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Neurofibromatoses - Products under Development by Companies
  • Neurofibromatoses - Products under Investigation by Universities/Institutes
  • Neurofibromatoses - Companies Involved in Therapeutics Development
    • Alexion Pharmaceuticals Inc
    • Arno Therapeutics Inc
    • AstraZeneca Plc
    • Betta Pharmaceuticals Co Ltd
    • Celldex Therapeutics Inc
    • Lixte Biotechnology Holdings Inc
    • Novartis AG
    • Plex Pharmaceuticals Inc
  • Neurofibromatoses - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-42 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • asfotase alfa - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-0158 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FRAX-597 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • icotinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LB-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OS-342 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Neurofibromatoses Type I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VAL-0524 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neurofibromatoses - Dormant Projects
  • Neurofibromatoses - Discontinued Products
  • Neurofibromatoses - Product Development Milestones
    • Featured News & Press Releases
      • May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neurofibromatoses, H2 2016
  • Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Neurofibromatoses - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Neurofibromatoses - Pipeline by Arno Therapeutics Inc, H2 2016
  • Neurofibromatoses - Pipeline by AstraZeneca Plc, H2 2016
  • Neurofibromatoses - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016
  • Neurofibromatoses - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Neurofibromatoses - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
  • Neurofibromatoses - Pipeline by Novartis AG, H2 2016
  • Neurofibromatoses - Pipeline by Plex Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Neurofibromatoses - Dormant Projects, H2 2016
  • Neurofibromatoses - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Neurofibromatoses, H2 2016
  • Number of Products under Development for Neurofibromatoses - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top